Mirum Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 89 to 92.
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
Mirum Pharmaceuticals is building a consolidation with a 48.89 entry. See if it can clear the breakout price in volume at least 40% above average.
The company posted 0% earnings growth last quarter. Sales rose 89%.
The company earns the No. 23 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
